Novo Nordisk A/S (NVO)
NYSE: NVOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NVO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $166.69B
- P/E (TTM)
- 9.55
- Forward P/E
- 10.77
- EPS (TTM)
- $3.96
- Dividend yield
- 30.94% ($11.70)
- Ex-dividend date
- Aug 17, 2026
- 52-week range
- 35.12 – 64.16
- Day range
- 37.75 – 39.11
- Volume / Avg
- 13.04M / 12.59M
- Beta
- —
- Shares outstanding
- 3.33B
- Next earnings
- Feb 3, 2027
52-week range
NVO stock today
Shares of Novo Nordisk A/S (NVO) finished lower on Nov 20 at $37.82, a drop of 2.70% or $1.05 per share, versus the S&P 500's 3.70% decline. Shares are 41.1% below their 52-week high of $64.16, set on Jan 23, 2026 and 7.7% above the 52-week low of $35.12, near the bottom of the past year's range. NVO is down 25.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 20.6%.
At 9.6x trailing earnings, Novo Nordisk A/S trades below the peer-group median of 23.1x. Its forward P/E of 10.8x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year. Novo Nordisk A/S's next earnings report is expected on Feb 3, 2027. Novo Nordisk A/S pays an annual dividend of $11.70 per share, a 30.94% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Novo Nordisk A/S
Company profileNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Maziar Mike Doustdar B.A.
- Headquarters
- Bagsvaerd
- Employees
- 68,794
- Website
- novonordisk.com
Analyst forecast
ForecastConsensus (14 analysts)
hold
Avg. price target
$45.49+20.28%
- Strong buy 0
- Buy 3
- Hold 10
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Feb 3, 2027
- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $1.02 vs $0.81
- Surprise
- +25.93%
Dividends
Dividend history- Annual dividend
- $11.70
- Dividend yield
- 30.94%
- Last payment
- $0.579
- Ex-dividend date
- Aug 17, 2026
NVO news
All NVO news- $1,000 Invested in Eli Lilly 5 Years Ago Is Now Worth Over $5,000. Could It Soar That Much Again by 2031?NasdaqLLY, NVO
- Novo Nordisk's Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy?NasdaqNVO, LLY, PFE
- Lilly vs. Pfizer: Which Drugmaker Has Stronger Growth Prospects?NasdaqPFE, LLY, NVO
- Forget the Headlines: Novo Nordisk's (NVO) 4.6% Dividend Yield Is the Real Story for Patient InvestorsNasdaqNVO, UHAL.B
- Novo Nordisk: A Return To Growth May Be Just Around The CornerSeeking Alpha
- Can New Products and Acquisitions Revive Pfizer's Growth Story?NasdaqPFE, NVO, LLY
- Novo Nordisk: The Worst May Be BehindSeeking Alpha
- Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?NasdaqLLY, NVO
Novo Nordisk A/S peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PFEPfizer Inc. | 27.40 | -0.51% | $156.18B | vs NVO |
| ABTAbbott Laboratories | 103.00 | -0.84% | $178.39B | vs NVO |
| VRTXVertex Pharmaceuticals Incorporated | 515.02 | -1.08% | $130.58B | vs NVO |
| BMYBristol-Myers Squibb Company | 58.80 | +0.79% | $120.19B | vs NVO |
| SNYSanofi ADS | 46.52 | +1.00% | $111.70B | vs NVO |
| GSKGSK plc ADR | 47.76 | -0.13% | $95.73B | vs NVO |
| REGNRegeneron Pharmaceuticals Inc. | 920.69 | -0.19% | $95.24B | vs NVO |
| TAKTakeda Pharmaceutical Company Limited ADR | 21.77 | +1.68% | $69.55B | vs NVO |
Indexes, lists and sector
Novo Nordisk A/S stock FAQ
What is Novo Nordisk A/S's stock price today?
NVO last traded at $37.82 as of Nov 20, 4:00 PM EST, down 2.70% on the day. Prices are delayed at least 15 minutes.
Does Novo Nordisk A/S pay a dividend?
Yes. Novo Nordisk A/S pays $11.70 per share annually, a 30.94% yield. The most recent dividend of $0.579 had an ex-dividend date of Aug 17, 2026.
When is Novo Nordisk A/S's next earnings date?
Novo Nordisk A/S is expected to report earnings on Wednesday, February 3, 2027.
What is NVO's P/E ratio?
NVO trades at a trailing P/E ratio of 9.55 and a forward P/E of 10.77, compared with a median of 23.1 for its closest peers.
Who is Novo Nordisk A/S's CEO?
Mr. Maziar Mike Doustdar B.A. is the chief executive officer of Novo Nordisk A/S, which has about 68,794 employees.
Has NVO ever split its stock?
Yes. The most recent NVO stock split was a 2-for-1 split on Sep 20, 2023, one of 5 splits on record.
What is the NVO 52-week high?
The 52-week high for NVO is $64.16 and the 52-week low is $35.12. The stock is currently 41.1% below its high.